VI
Viracta Therapeutics, Inc.
VIRX · OTC
$0.01 +0.00% (+$0.00)
Piotroski F-Score Weak
2/9Valuation
-
N/A EV/EBITDA N/A
P/S N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
-
N/A ROE N/A
ROA N/A
Asset turnover N/A
Debt
-
N/A Current ratio N/A
Int. coverage N/A
Net debt/EBITDA N/A
Stability
8 /100
Unstable EPS volatility 673.57%
Profitable years 0
Beta 0.28x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VIRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Craig R. Jalbert
Employees
26
Headquarters
Cardiff-by-the-Sea